N-Cyclohexyl-3-(piperazin-1-yl)propanamide | 79379-31-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-Cyclohexyl-3-(piperazin-1-yl)propanamide
• 英文别名: N-cyclohexyl-3-piperazin-1-ylpropanamide
• CAS: 79379-31-0
• 化学式: C₁₃H₂₅N₃O
• 分子量: 239.36
• InChiKey: OGMPDQCCEHBAFY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  44.4
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] NEW COMPOUNDS VII<br/>[FR] NOUVEAUX COMPOSÉS VII
  申请人：BIOVITRUM AB PUBL

  公开号：WO2009147219A1

  公开（公告）日：2009-12-10

  The present invention relates to new compounds of formula (I), to pharmaceutical compositions comprising these compounds and to the use of these compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associated with weight gain, type 2 diabetes and dyslipidemias.

  本发明涉及式(I)的新化合物，包含这些化合物的药物组合物，以及这些化合物作为瘦素受体调节剂模拟物在制备用于治疗与体重增加、2型糖尿病和血脂异常相关的药物的用途。
• New Compounds VII
  申请人：Chapman Emma

  公开号：US20110275670A1

  公开（公告）日：2011-11-10

  The present invention relates to new compounds of formula (I), to pharmaceutical compositions comprising these compounds and to the use of these compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associated with weight gain, type 2 diabetes and dyslipidemias.

  本发明涉及一种新的化合物（I）的配方，以及包含这些化合物的制药组合物和使用这些化合物作为瘦素受体调节剂模拟物的用途，用于制备治疗与体重增加、2型糖尿病和血脂异常相关的药物。
• NEW COMPOUNDS VII
  申请人：AstraZeneca AB

  公开号：EP2321276A1

  公开（公告）日：2011-05-18
• ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME
  申请人：Melinta Therapeutics, Inc.

  公开号：EP2488532B1

  公开（公告）日：2018-05-09
• Substituted Cyclohexylamine Compounds
  申请人：EPIZYME, INC.

  公开号：US20170362191A1

  公开（公告）日：2017-12-21

  The present disclosure provides substituted cyclohexylamine compounds having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein R 1 , R 2a , R 2b , R 3a , R 3b , R 4 , R 5 , and R 7 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD 3 or SMYD 2 . Compounds of the present disclosure are especially useful for treating cancer.